Shortly after these publications, and armed with the first anti-tau monoclonal antibody, the Binder group and collaborators tested Tau1 reactivity in AD brain sections (Grundke-Iqbal et al., 1986; Wood et al., 1986). This evidence concerns the gene MAPT and Alzheimer disease.